Skip to content
Genetic Analysis
Genetic Analysis
  • Home
  • About us
    • How we work
    • Management
    • Board of Directors
    • Partnerships
  • Products
    • Service Products
      • The GA-map® Dysbiosis Test Lx
      • The GA-map® COVID-19 Fecal Test Kit
    • Lab Products
      • The GA-map® Dysbiosis Lx reagent kit
      • The GA-map® COVID-19 reagent kit
  • News
    • Press Releases
    • News
  • Investors
    • Investor News
      • Press Releases
    • Financial Reports
    • Financial Calendar
    • Share Information
    • Analyst Coverage
    • IPO 2021
    • Corporate Governance
    • Primary Insiders
    • IR Contacts
  • Order
  • Contact us
Genetic Analysis
  • Home
  • About us
    • How we work
    • Management
    • Board of Directors
    • Partnerships
  • Products
    • Service Products
      • The GA-map® Dysbiosis Test Lx
      • The GA-map® COVID-19 Fecal Test Kit
    • Lab Products
      • The GA-map® Dysbiosis Lx reagent kit
      • The GA-map® COVID-19 reagent kit
  • News
    • Press Releases
    • News
  • Investors
    • Investor News
      • Press Releases
    • Financial Reports
    • Financial Calendar
    • Share Information
    • Analyst Coverage
    • IPO 2021
    • Corporate Governance
    • Primary Insiders
    • IR Contacts
  • Order
  • Contact us

Eilert Aamodt

Genetic Analysis AS (GEAN): First day of trading in Genetic Analysis shares and warrants on Spotlight Stock Market

2021-10-012021-10-01

Genetic Analysis AS (GEAN): Disclosure of Large Shareholding

2021-09-24

Genetic Analysis AS (GEAN): Registration of share capital increase

2021-09-24

Genetic Analysis AS (GEAN): Minutes from the Extraordinary General Meeting

2021-09-222021-09-20

Genetic Analysis AS (GEAN): Mandatory notification of trade

2021-09-242021-09-15

Genetic Analysis AS (GEAN) : IPO prior to listing was significantly oversubscribed

2021-09-222021-09-15

Genetic Analysis AS (GEAN): Notice of Extraordinary General Meeting

2021-09-222021-09-13

The subscription period begins in Genetic Analysis AS issue of units prior to planned listing on Spotlight Stock Market

2021-09-222021-08-30

Genetic Analysis AS receives preliminary approval for listing and publishes prospectus in connection with planned IPO

2021-09-222021-08-24

Genetic Analysis AS releases Interim report January – June 2021

2021-09-222021-08-20
Post navigation
Newer posts
← Previous Page1 Page2 Page3

Genetic Analysis AS is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients.

Contact

Phone: +47 48 32 16 10
E-mail: info@genetic-analysis.com
Address: Genetic Analysis AS, Kabelgata 8
0580 Oslo, Norway

Open Google Maps
Connect

LinkedIn

Facebook

Twitter

Navigate

Contact Us

Terms of Use

Privacy Policy

© 2021 Genetic Analysis

  • Home
  • About us
    • How we work
    • Management
    • Board of Directors
    • Partnerships
  • Products
    • Service Products
      • The GA-map® Dysbiosis Test Lx
      • The GA-map® COVID-19 Fecal Test Kit
    • Lab Products
      • The GA-map® Dysbiosis Lx reagent kit
      • The GA-map® COVID-19 reagent kit
  • News
    • Press Releases
    • News
  • Investors
    • Investor News
      • Press Releases
    • Financial Reports
    • Financial Calendar
    • Share Information
    • Analyst Coverage
    • IPO 2021
    • Corporate Governance
    • Primary Insiders
    • IR Contacts
  • Order
  • Contact us